Navigation Links
New HydraSolve™ Lipoplasty System launched at American Society of Aesthetic Plastic Surgery Meeting
Date:5/4/2012

IRVINE, Calif., May 4, 2012 /PRNewswire/ -- Andrew Technologies, LLC launched the HydraSolve™ Lipoplasty System today at the American Society of Aesthetic Plastic Surgery (ASAPS) in Vancouver, BC. ASAPS is the leading plastic surgery medical conference for surgeons focused on aesthetic body contouring and is attended by approximately 3,000 plastic surgeons.

(Photo: http://photos.prnewswire.com/prnh/20120504/NY98979 )

HydraSolve™ is an FDA-cleared liposuction device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device for precision cataract surgery. HydraSolve™ combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve™ cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue.  It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not damaging or cutting blood vessels, nerves or connective tissue. HydraSolve™ achieves liquefaction of fat tissue by cell disaggregation, not by the lysing of cell membranes.

The HydraSolve™ system is displayed at booth #333. There is also a Hot Topics presentation today by Dr. Richard D'Amico (past-President of ASPS) where Dr. D'Amico will highlight his clinical experiences with HydraSolve. Additionally, Andrew Technologies has submitted two e-Posters. Scientific poster # 5266 provides data from the safety studies supporting our FDA clearance, Scientific poster # 5233 provides results of the largest consumer survey ever reported in Lipoplasty with 21,509 respondents.

Since the 2010 FDA clearance of HydraSolve™, Andrew Technologies has been engaged in clinical development of the device with several leading Plastic Surgeons to demonstrate the full potential of HydraSolve in over 50 patient cases. According to Dr. Richard D'Amico of Englewood, N.J., "It is clearly more efficient and my opinion is that it is less traumatic and may result in less blood loss for a given amount of lipoaspirate." Dr. Christopher Godek of Toms River, NJ, and President of the NJ Society of Plastic Surgery, has contributed to the development of the HydraSolve™ technology since its inception and observed that "HydraSolve™ provides faster, smoother fat extraction for the surgeon, with a quicker recovery for patients."  Dr. David Abramson, another expert plastic surgeon in New York and New Jersey has more recently started using HydraSolve and added, "With the first patient I treated, on her first post-op visit I had to actively search for some bruising and almost didn't find any."

Dr. Mark S. Andrew, who co-invented HydraSolve™ and related technologies, is now Chief Scientific Officer of Andrew Technologies and has been directly involved with all of the research and development of HydraSolve™.  According to Dr. Andrew, "HydraSolve™ is better for patients because it is gentle and tissue-friendly; it's better for surgeons because it gives them excellent control and precision in removing fat, and it also reduces their physical exertion."

About HydraSolve Lipoplasty System

HydraSolve™ Lipoplasty System is an all-American technology. It was invented in New Jersey, designed in Virginia by MPR Associates http://www.mpr.com/ , and manufactured in Ohio and Massachusetts by Sparton Medical http://www.sparton.com/strategic-business-units/medical/  and STD Medical http://www.stdmed.com/ . We anticipate that HydraSolve™ will be very successful in the US launch, and in the key export markets of Europe, Asia, and South America.

About Andrew Technologies, LLC

Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics. Andrew Technologies is a venture capital funded company that will be based in Orange County, CA. Our primary investors are WFD Ventures and the New Jersey Technology Council.

About MPR Associates

MPR is a fully integrated product development, engineering, and industrial design company specializing in turn-key product development services in life sciences industries for companies manufacturing medical devices, diagnostics, laboratory instruments, and pharmaceuticals. We handle all aspects of product development from industrial design, mechanical and electrical design, software development, and V&V activities to rapidly prototype full systems, fabricate units for clinical trials and pilot manufacturing, and manage technology transfer activities to manufacturers for full-scale production. 

About Sparton Medical

Sparton Medical's operations are comprised of contract development, design, production and fulfillment of complex and sophisticated medical class I, class II, and class III devices in its FDA registered and ISO 13485 certified facilities.  We assure product reliability and safety in accordance with Food and Drug Administration ("FDA") guidelines and GMP manufacturing procedures for each product we design and manufacture. Sparton Medical specializes in systems and procedures that meet the requirements of medical OEM and emerging technology customers in the In Vitro Diagnostic Therapeutic and Surgical Devices market segments.

About STD Med

STD Med is a full service contract manufacturer and developer of medical devices and precision machine components. Having been in business since 1953, this privately held company began its history as Stoughton Tool and Die. Later named STD Manufacturing, the company's core competency was in machining for the Aerospace, Defense and Commercial Industries. In 1990 STD's vision changed as it began its transition into the Medical Device Industry. As a result, the company renamed itself and STD Med emerged.  Housed in several facilities, totaling over 150 thousand square feet, STD Med is vertically integrated, offering complete supply chain management and providing a single point of contact for its customers.


'/>"/>
SOURCE Andrew Technologies, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MEDRAD Installs First Intego(TM) PET Infusion System
2. RainDance Technologies Appoints Olex Vice President, System Development
3. Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
4. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
5. North Dakota Pharmacists and Medication Management Systems Partner to Deliver Quality MTM Services to Patients With Diabetes
6. CSL Behrings Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients
7. Avantis Medical Systems, Inc. Announces Key Leadership Appointments
8. MedPro Installs 1000th Ultrasound System Worldwide
9. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
10. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
11. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... - New FDA action date of July 22, ... July 22, 2016   --> - ... 2016   - Lifitegrast has the potential to be ... of signs and symptoms of dry eye disease in adults ... only product approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... Feb. 4, 2016 Sinovac Biotech Ltd. ("Sinovac" ... provider of biopharmaceutical products in China ... board of directors received on February 4, 2016 a ... a consortium comprised of PKU V-Ming ( Shanghai ... Ltd., CICC Qianhai Development ( Shenzhen ) ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, ... focused on developing aerosolized KL4 surfactant therapies for ... Directors has approved an inducement award as a ... , its newly appointed President and Chief Executive ... Compensation Committee on February 1, 2016 and granted ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the world-leading ... and publication industries, will provide the data management solution ... (NPSC). ... Phenotypic analysis measures the ... organisms, allowing comparisons between states such as health and ...
Breaking Biology News(10 mins):